Avrobio shares blasted after trial update sours outlook on gene therapy for Fabry disease
Avrobio made the leap onto Nasdaq a few months ago and then proceeded to run the table largely on a snapshot of efficacy for its lead gene therapy to treat Fabry disease. On Monday, though, an updated look at a key data point sent investors running, collapsing the share price.
By the end of the day on Monday Avrobio’s stock $AVRO had been beaten down 52%, wiping out hundreds of millions of dollars in market cap.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
